Linked Life Data

21414556

Source:http://linkedlifedata.com/resource/pubmed/id/21414556

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2011-3-18
pubmed:abstractText
The number of clinical trials for Alzheimer's disease conducted outside the United States in a broad array of countries is increasing. As the number of compounds ready for clinical testing increases, and as trials become longer and more complex, this trend is expected to grow. The cultural and ethical context of global clinical trials, potential benefits for those involved, and practical approaches to obstacles generated by these global trials were discussed at a meeting of the Alzheimer's Association Research Roundtable. Regulatory issues, including regional differences in study registration procedures, rules for collecting and reporting serious adverse events, requirements for national identity of study populations, and regulatory audits were also discussed by individuals who are knowledgeable about global clinical trials for Alzheimer's disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1552-5279
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
197-207
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Global issues in drug development for Alzheimer's disease.
pubmed:affiliation
Baylor College of Medicine, Houston, TX, USA. rdoody@bcm.edu
pubmed:publicationType
Journal Article